Lower urinary tract transitional cell carcinoma in cats: Clinical findings, treatments, and outcomes in 118 cases
Maureen A. GriffinWilliam T. N. CulpMichelle A. GiuffridaPeter EllisJoanne TuohyJames A. PerryAllison GedneyCassie N. LuxMilan MilovancevMandy L. WallaceJonathan HashKyle G. MathewsJulius M. LiptakLaura E. SelmicAmeet SinghCarrie A. PalmIngrid M. BalsaPhilipp D. MayhewMichele A. SteffeyRobert B. RebhunJenna H. BurtonMichael S. Kent
25
Citation
32
Reference
10
Related Paper
Citation Trend
Abstract:
Abstract Background Lower urinary tract transitional cell carcinoma (TCC) is an important but rarely described disease of cats. Objectives To report the clinical characteristics, treatments, and outcomes in a cohort of cats with lower urinary tract TCC and to test identified variables for prognostic relevance. Animals One‐hundred eighteen client‐owned cats with lower urinary tract carcinoma. Methods Medical records were retrospectively reviewed to obtain information regarding clinical characteristics, treatments, and outcomes. Recorded variables were analyzed statistically. Results Median age of affected cats was 15 years (range, 5.0‐20.8 years) and median duration of clinical signs was 30 days (range, 0‐730 days). The trigone was the most common tumor location (32/118; 27.1%) as assessed by ultrasound examination, cystoscopy, or both. Treatment was carried out in 73 of 118 (61.9%) cats. Metastatic disease was documented in 25 of 118 (21.2%) cats. Median progression‐free survival and survival time for all cats were 113 days (95% confidence interval [CI], 69‐153) and 155 days (95% CI, 110‐222), respectively. Survival increased significantly ( P < .001) when comparing cats across the ordered treatment groups: no treatment, treatment without partial cystectomy, and treatment with partial cystectomy. Partial cystectomy (hazard ratio [HR], 0.31; 95% CI, 0.17‐0.87) and treatment with nonsteroidal anti‐inflammatory drugs (HR, 0.55; 95% CI, 0.33‐0.93) were significantly associated with longer survival times. Conclusions and Clinical Importance The results support treatment using partial cystectomy and NSAIDs in cats with TCC.Bladder cancer is one of the most common cancers worldwide causing a significant burden on healthcare system and society. Muscle-invasive bladder cancer (MIBC) is highly fatal, and if untreated, >85% of patients die within 2 years of diagnosis. Although radical cystectomy (RC) is the preferred treatment of choice in patients with MIBC, bladder preservation can be considered in patients who are either not eligible for cystectomy or are not willing to undergo cystectomy. The goal of bladder preservation is to achieve cancer survival at least equivalent to RC and to maintain better quality of life including sexual function. Strategies for bladder preservation include partial cystectomy, radical transurethral resection, radiation therapy, and chemotherapy. It is widely accepted that combination of these approaches could result in better outcomes in patients with MIBC. In this review, we describe different approaches for bladder preservation and their outcomes.
Cite
Citations (2)
Background and purpose:For muscle-invasive bladder caner patients,the recommended treatment is radical cystectomy.While some patients are not suitable or unwilling to this treatment,bladder preserving treatment provides another choice.This research aimed to assess the curative effect,influencing factors of partial cystectomy plus chemotherapy for muscle-invasive bladder cancer.Methods:From Jan.2002 to Apr.2005,52 patients with muscle-invasive bladder cancer underwent partial cystectomy plus chemotherapy(PC group),contrast to 47 patients which underwent radical cystectomy(RC group).The overall survival rates(OS) of the two groups were analyzed.Results:There is no significant difference of overall survival between the two groups(P=0.279).For stage T3 and recurrent patients the PC group had significantly lower survival rates than RC group(P=0.048).Conclusion:Partial cystectomy plus chemotherapy provides a choice for the treatment of muscle-invasive bladder cancer.
Cite
Citations (0)
Bladder cancer is a common malignancy seen in older adults with coexisting medical illnesses. The management of patients with muscle invasive disease includes perioperative chemotherapy and radical cystectomy; however, patients may decline surgery and older patients with comorbid conditions may not be candidates for surgery and thus alternative treatment strategies are needed. Trimodality bladder preservation protocols for muscle invasive bladder cancer have generally included only those patients who are candidates for a salvage cystectomy. In this review, we discuss the current status of bladder preservation treatment options for patients with muscle-invasive disease who are not candidates for cystectomy or who decline surgery and highlight the need for clinical trials investigating novel treatment approaches in this older patient population.
Cite
Citations (24)
Urothelial cancer
Cite
Citations (4)
In the U.S., radical cystectomy has long been considered the standard of care for patients with muscle-invasive bladder cancer. However, radical cystectomy (with or without the creation of an orthotopic diversion) is a complex surgical procedure requiring intensive perioperative support services, and most patients with muscle-invasive disease are older than 70. During the past 2 decades, patients treated at academic centers have …
Urinary diversion
Radical surgery
Cite
Citations (0)
Cite
Citations (0)
Bladder cancer is the 4th commonest malignancy in the United Kingdom and worldwide there are nearly 400,000 new cases every year with over 150,000 deaths. The gold standard treatment for muscle invasive bladder cancer is radical cystectomy with neoadjuvant chemotherapy. Despite this the overall survival at 5 years is only around 50%. To improve outcomes new pre-clinical models of greater physiological relevance are needed and the ability to translate research from the laboratory to clinical practice needs to be improved. The tyrosine kinase HER2 is an attractive therapeutic target in bladder cancer and has the potential to be used in clinical practice. The hypothesis of this thesis was that HER2 would be a prognostic biomarker in patients with bladder cancer requiring radical cystectomy and that it has a critical role in bladder cancer cell invasiveness. To test this the aims were firstly to create a novel three dimensional cell culture to be used as a more physiological method of studying the invasiveness of bladder cancer. Secondly a tissue micro-array and associated database of cystectomy patients was created for biomarker discovery and to investigate the role of HER2 and its family members as biomarkers in patients with bladder cancer treated with cystectomy. The novel three dimensional organotypic model was successfully optimized and its ability to reproduce invasive characteristics confirmed with primary invasive cancer cells harvested from a cystectomy patient. Lenti-viral knockdown of HER2 failed to affect the invasive nature of the T24 cell line. The TMA consisted of 226 cystectomy patients treated over a 10-year period with a median follow up of 49 months. The 5-year overall survival was 48.8% with a cancer specific survival of 62.1% and 27.4% of patients received neo-adjuvant chemotherapy. 17% of patients overexpressed HER2 and HER2 was an independent risk factor for worse overall survival with a hazard ratio of 1.66. Other biomarkers screened for included Nrf-2, which this TMA suggests predicts response to cisplatin based chemotherapy, AIMP3 which may predict resistance to radiation when down regulated and b-HCG, which demonstrated a potential role as a marker of recurrence when measured in blood serum. In conclusion, HER2 appears to be prognostic of poor outcome in this cohort but is not critical for bladder cancer invasion in the organotypic model. The process of testing this has created two valuable models for biomarker discovery that will be used in future research.
Clinical Significance
Cite
Citations (0)
Nephrology
Cite
Citations (6)
Cite
Citations (0)
Bladder cancer represents a significant source of morbidity and mortality worldwide. Nearly 430,000 diagnoses of bladder cancer are made each year leading to approximately 165,000 deaths (1). Within the context of healthcare spending it is a costly diagnosis and has been reported as the most expensive diagnosis per patient lifetime among all cancers (2,3), with a total cost of almost $4 billion annually in the United States in 2010 (4). Previous studies have shown that radical cystectomy (RC) accounts for the largest proportion of costs associated with bladder cancer care (5); however, few studies have evaluated the cost of trimodal therapy (TMT). TMT has progressively been accepted as a viable treatment option for the treatment of muscle-invasive bladder cancer (MIBC) (6-8) and therefore the implications from a healthcare economic perspective have become increasingly important to consider.
Cite
Citations (1)